MA42532A - ANTIBODY CONSTRUCTIONS FOR FLT3 AND CD3 - Google Patents

ANTIBODY CONSTRUCTIONS FOR FLT3 AND CD3

Info

Publication number
MA42532A
MA42532A MA042532A MA42532A MA42532A MA 42532 A MA42532 A MA 42532A MA 042532 A MA042532 A MA 042532A MA 42532 A MA42532 A MA 42532A MA 42532 A MA42532 A MA 42532A
Authority
MA
Morocco
Prior art keywords
flt3
antibody constructions
constructions
antibody
Prior art date
Application number
MA042532A
Other languages
French (fr)
Other versions
MA42532B1 (en
Inventor
Claudia Bluemel
Franziska Bott
Christoph Dahlhoff
Patrick Hoffmann
Elisabeth Nahrwold
Jochen Pendzialek
Tobias Raum
Original Assignee
Amgen Res Munich Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Res Munich Gmbh filed Critical Amgen Res Munich Gmbh
Priority claimed from PCT/EP2016/068319 external-priority patent/WO2017021362A1/en
Publication of MA42532A publication Critical patent/MA42532A/en
Publication of MA42532B1 publication Critical patent/MA42532B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
MA42532A 2015-07-31 2016-08-01 Antibody constructs for flt3 and cd3 MA42532B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562199944P 2015-07-31 2015-07-31
PCT/EP2016/068319 WO2017021362A1 (en) 2015-07-31 2016-08-01 Antibody constructs for flt3 and cd3

Publications (2)

Publication Number Publication Date
MA42532A true MA42532A (en) 2018-06-06
MA42532B1 MA42532B1 (en) 2023-05-31

Family

ID=60245275

Family Applications (1)

Application Number Title Priority Date Filing Date
MA42532A MA42532B1 (en) 2015-07-31 2016-08-01 Antibody constructs for flt3 and cd3

Country Status (2)

Country Link
AR (1) AR105561A1 (en)
MA (1) MA42532B1 (en)

Also Published As

Publication number Publication date
AR105561A1 (en) 2017-10-18
MA42532B1 (en) 2023-05-31

Similar Documents

Publication Publication Date Title
FR22C1048I2 (en) ANTI-CD3 ANTIBODIES AND METHODS OF USE
MA42925A (en) ANTI-TIGIT ANTIBODIES AND METHODS OF USE
MA43018A (en) ANTI-PD1 ANTIBODIES AND METHODS OF USE
MA46525A (en) ANTI-LAG-3 ANTIBODIES AND COMPOSITIONS
MA49043A (en) STABLE ANTIBODY FORMULATION
MA46529A (en) ANTI-LAG-3 ANTIBODIES AND PROCESSES FOR USE
MA43387A (en) ANTI-GITR ANTIBODIES AND THEIR METHODS OF USE
MA44381A (en) MULTISPECIFIC HETERODIMERIC ANTIBODY FORMAT
MA50948A (en) ANTIBODIES AND METHODS OF USING THE SAME
MA44659A (en) ANTI-TIM-3 ANTIBODIES AND COMPOSITIONS
MA50359A (en) ANTI-CD38 ANTIBODIES AND METHODS OF USE
MA43197A (en) BISPECIFIC ANTIBODY CONSTRUCTIONS FOR CDH3 AND CD3
MA48579A (en) ANTI-PD1 ANTIBODIES AND METHODS OF USING THEM
MA45123A (en) ANTI-TIM-3 ANTIBODIES AND THEIR METHODS OF USE
MA42043A (en) ANTI-OX40 ANTIBODIES AND METHODS OF USE THEREOF
MA49950A (en) ANTI-B7-H4 ANTIBODIES AND PROCEDURES FOR USE
MA50949A (en) ANTI-CTLA-4 ANTIBODIES AND PROCESSES FOR USE
MA53434A (en) ANTI-TIGIT ANTIBODIES
MA47849A (en) ANTI-GITR ANTIBODIES AND THEIR METHODS OF USE
MA42971A (en) ANTI-PDL1 ANTIBODIES, ACTIVABLE ANTI-PLD1 ANTIBODIES, AND METHODS OF USE THEREOF
MA53355A (en) ANTI-CTLA-4 ANTIBODIES AND METHODS OF USE THEREOF
MA52884A (en) ANTI-IL-11 ANTIBODIES
MA42447A (en) ANTI-PD-1 ANTIBODIES, ACTIVABLE ANTI-PD-1 ANTIBODIES, AND METHODS OF USE THEREOF
MA46057A (en) ANTI-CTLA4 ANTIBODIES
MA51552A (en) ANTI-OX40 ANTIBODIES AND METHODS OF USE